NASDAQ:CASI CASI Pharmaceuticals 8/29/2025 Earnings Report $0.21 0.00 (0.00%) As of 05/14/2026 ProfileEarnings HistoryForecast CASI Pharmaceuticals EPS ResultsActual EPS-$0.86Consensus EPS -$0.47Beat/MissMissed by -$0.39One Year Ago EPSN/ACASI Pharmaceuticals Revenue ResultsActual Revenue$4.18 millionExpected Revenue$6.28 millionBeat/MissMissed by -$2.10 millionYoY Revenue GrowthN/ACASI Pharmaceuticals Announcement DetailsQuarterDate8/29/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile CASI Pharmaceuticals Earnings HeadlinesCASI Pharmaceuticals stock plunges on Nasdaq delisting noticeFebruary 26, 2026 | za.investing.comWhat Drove CASI Pharmaceuticals' 24% Rise After Hours?February 26, 2026 | msn.comNobody Understands Why Trump Is Invading Iran (here’s the answer)Most investors are reacting to the Iran strikes without understanding the underlying motive driving the decision. Addison Wiggin, Founder of Grey Swan Investment Fraternity, says there is a hidden reason behind the bombing - and knowing it could change how you position your money right now.May 15 at 1:00 AM | Banyan Hill Publishing (Ad)CASI Pharmaceuticals Fails to Renew FOLOTYN Import License in China, Halts SalesJanuary 24, 2026 | theglobeandmail.comCASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated RejectionJanuary 15, 2026 | finanznachrichten.deCASI Pharmaceuticals wins Nasdaq listing extension to February 2026December 23, 2025 | msn.comSee More CASI Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CASI Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CASI Pharmaceuticals and other key companies, straight to your email. Email Address About CASI PharmaceuticalsCASI Pharmaceuticals (NASDAQ:CASI), Inc. is a clinical‐stage biopharmaceutical company focused on the development and commercialization of innovative therapies in oncology and immunology. The company leverages a combination of small‐molecule targeted drugs and biologics to address high‐unmet medical needs in cancer and autoimmune diseases. CASI’s R&D efforts emphasize the discovery and advancement of compounds that modulate key signaling pathways, with a goal of delivering differentiated treatment options to patients worldwide. The company’s lead clinical candidate is famitinib, a multi‐targeted tyrosine kinase inhibitor that has been evaluated in various solid tumors, including gastric, breast and renal cancers. In addition to famitinib, CASI is advancing an immuno-oncology portfolio that includes checkpoint inhibitors and novel immune modulators designed to enhance antitumor responses. Preclinical programs focus on next‐generation molecules with potential applications in both oncology and inflammatory disorders, building on the company’s proprietary discovery platform. Founded by a team of biotech entrepreneurs and scientists, CASI Pharmaceuticals is headquartered in Beijing, with research and development operations in Shanghai and a presence in North America to support global clinical activities. The company has established strategic partnerships with academic institutions and contract research organizations to accelerate its clinical trials and expand its pipeline. CASI’s leadership team comprises industry veterans with extensive experience in drug development and regulatory affairs, guiding the company through key milestones as it pursues regulatory approvals and commercial readiness.View CASI Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Datavalut Gains Traction: 5 Reasons to Sell NowTMC Stock: Why This Pre-Revenue Miner Is Worth WatchingViking Sails to All-Time Highs—Fundamentals Signal More to ComeYETI Rallies After Earnings Beat and Raised OutlookAeluma's Post-Earnings Dip Creates a Buying OpportunityCisco’s Vertical Rally May Still Be in the Early InningsKarman: Defense Darling's Outlook Strengthens After 40% Drop Upcoming Earnings Palo Alto Networks (5/19/2026)Home Depot (5/19/2026)Keysight Technologies (5/19/2026)Analog Devices (5/20/2026)Intuit (5/20/2026)NVIDIA (5/20/2026)Lowe's Companies (5/20/2026)Medtronic (5/20/2026)Target (5/20/2026)TJX Companies (5/20/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
